Dr Reddy’s Laboratories Shares Extend Rise to 6th Consecutive Day, Hitting New 52-Week High on High Volumes

Dr Reddy’s Laboratories share price has advanced for the sixth consecutive trading session, gaining 4.17% to Rs 1,406.80 and touching a new intraday 52-week high of Rs 1,414.90 in today’s session. Trading volumes have surged past 4 million shares, well above the stock’s daily average, signalling institutional accumulation behind the move. The six-session winning streak has coincided with a broad-based rally in the Nifty Pharma index, which is the top performing sector today at +1.73%, providing powerful sectoral tailwinds to Dr Reddy’s share price.

The breakout above the previous 52-week high of Rs 1,375.90 is a technically significant event that chartists typically view as a continuation signal. The move comes against a backdrop of positive news flow including product launches in semaglutide, biosimilar pipeline progress and a Nomura Buy rating with a target of Rs 1,740. The USFDA recently issued a Form 483 with seven observations at the company’s Bachupally biologics facility after a Pre-License Inspection, but investors are treating the development as a standard regulatory checkpoint rather than a material risk, given the company’s track record of resolving similar observations.

Click Here – Get Free Investment Predictions

Dr Reddy’s Share Price: Live Trading Data

Metric	Value
CMP (NSE)	Rs 1,406.80 (+4.17%, +Rs 56.30)
Previous Close	Rs 1,350.50
Intraday High (New 52W High)	Rs 1,414.90
Intraday Low	Rs 1,355.80
Previous 52-Week High	Rs 1,375.90 (now surpassed)
52-Week Low	Rs 1,148.40
Session Volume	4 million+ shares (elevated)
Consecutive Gain Days	6th session
Nifty Pharma Index	25,402 (+1.73%) – top sector today
Nomura Target	Rs 1,740 (Buy rating)

Track Dr Reddy’s Share Price Live on Univest Screener

Why Dr Reddy’s Share Price Is Rising for 6 Consecutive Days

Three converging catalysts are behind the Dr Reddy’s share price six-day rally. First, the Nifty Pharma index has broken above the key 25,000 weekly resistance level and is up 1.73% today, providing a sectoral momentum lift to all pharma heavyweights. The Indian Pharmaceutical Market recorded 12.1% year-on-year growth in May 2026, its sixth consecutive month above 10%, driven by volume, pricing and new product introduction simultaneously. This is a rare trifecta that supports broad-based re-rating for domestic pharma companies.

Second, Dr Reddy’s has a rich near-term product pipeline. The company became the first to receive Canadian approval for generic semaglutide injection, launched the product in India as Obeda on day one, and has received USFDA acceptance for review of its abatacept biosimilar IV biologics licence application. It also expanded its women’s health portfolio by acquiring Progynova and Cyclo-Progynova. Nomura recently upgraded its target price to Rs 1,740, reiterating Buy, citing the company’s strategic shift toward branded generics as a valuation re-rating catalyst.

Dr Reddy’s USFDA Form 483: Seven Observations Explained

The USFDA completed a Pre-License Inspection at Dr Reddy’s biologics manufacturing facility in Bachupally, Hyderabad, between June 16 and June 25, issuing Form 483 with seven observations. A Form 483 is issued when USFDA inspectors identify conditions that may constitute deviations from current Good Manufacturing Practices. It is an initial communication, not a Warning Letter, Import Alert or Complete Response Letter. Companies are given a stipulated timeline to file a corrective action plan. Dr Reddy’s has confirmed it will address all observations within the required timeframe. A previous Pre-Approval Inspection at the same Bachupally facility in September 2025 had issued five observations, which were resolved without material consequence. Investors are applying the same interpretation to today’s seven-observation Form 483.

Download the Univest iOS App or Univest Android App to access Dr Reddy’s live price, analyst research and portfolio tools on Univest.

What Investors Should Watch Next

Key monitorables for the Dr Reddy’s share price going forward include the corrective action plan response to the seven USFDA Form 483 observations, the USFDA review timeline for the abatacept biosimilar BLA, semaglutide market reception in India and Canada, and quarterly results guidance on margin and revenue trajectory. With a new 52-week high set today at Rs 1,414.90 and Nomura’s target at Rs 1,740, the stock still has significant headroom if the company’s execution remains on track. Technically, sustaining above the previous high of Rs 1,375.90 on any near-term pullback would confirm the breakout. Always consult a SEBI-registered financial advisor before investing.

Frequently Asked Questions

Why is Dr Reddy’s share price rising for 6 consecutive days?

Ans. Dr Reddy’s share price has risen for six consecutive sessions driven by three factors: the Nifty Pharma index rallying on strong domestic IPM growth of 12.1% YoY, positive pipeline catalysts including first-in-Canada semaglutide approval and abatacept biosimilar BLA acceptance by the USFDA, and a Nomura Buy rating with target price of Rs 1,740.

What is the USFDA Form 483 with seven observations for Dr Reddy’s?

Ans. The USFDA completed a Pre-License Inspection at Dr Reddy’s biologics facility in Bachupally, Hyderabad (June 16-25), and issued Form 483 with seven observations. A Form 483 identifies potential GMP deviations and is not a Warning Letter or Import Alert. Companies have a stipulated timeline to submit corrective action plans. Dr Reddy’s has confirmed it will address all observations within the required timeframe.

What is the new 52-week high for Dr Reddy’s share price?

Ans. Dr Reddy’s set a new 52-week high of Rs 1,414.90 in today’s intraday session, surpassing the previous 52-week high of Rs 1,375.90. The current trading price is Rs 1,406.80, up 4.17%. The 52-week low is Rs 1,148.40, representing a 22.5% gain from that low to the current price.

What is Nomura’s target price for Dr Reddy’s?

Ans. Nomura has a Buy rating on Dr Reddy’s with a target price of Rs 1,740, implying approximately 23.7% upside from the current price of Rs 1,406.80. Nomura cites the company’s strategic shift toward branded generics, biosimilar pipeline and women’s health portfolio expansion as key catalysts for valuation re-rating.

What products are driving the Dr Reddy’s share price rally?

Ans. Key products supporting the Dr Reddy’s share price rally include: generic semaglutide injection approved in Canada (first company) and launched in India as Obeda; abatacept biosimilar IV biologics licence application accepted by USFDA for review; women’s health portfolio expanded with Progynova and Cyclo-Progynova acquisitions; and Bosutinib 400mg launched in the US under first-to-file category.

What volumes are Dr Reddy’s shares trading at today?

Ans. Dr Reddy’s is trading on volumes exceeding 4 million shares in today’s NSE session, significantly above the daily average volume. High volume confirmation of a 52-week high breakout is a technically significant signal that often indicates institutional buying and can sustain directional momentum in the stock.